Results 111 to 120 of about 8,222 (211)

Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability

AAPS PharmSciTech, 2018
Vardenafil hydrochloride is commonly used for the curing of erectile dysfunction. VAR suffers certain limitations: (i) short elimination half-life (4–5 h), (ii) low aqueous solubility (0.11 mg/mL), (iii) susceptibility to extensive first-pass metabolism ...
M. A. Tawfik, M. I. Tadros, M. Mohamed
semanticscholar   +1 more source

Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice.

PLoS ONE, 2013
Although lung disease is the major cause of mortality in cystic fibrosis (CF), gastrointestinal (GI) manifestations are the first hallmarks in 15-20% of affected newborns presenting with meconium ileus, and remain major causes of morbidity throughout ...
Barbara Dhooghe, Sabrina Noël, Caroline Bouzin, Gaëtane Behets-Wydemans, Teresinha Leal   +4 more
doaj   +1 more source

Etiology and Management of Sexual Dysfunction [PDF]

, 2009
Sexual dysfunction is the impairment or disruption of any of the three phases of normal sexual functioning, including loss of libido, impairment of physiological arousal and loss, delay or alteration of orgasm.
Bevinahalli Nanjegowda, Raveesh, Muthugaduru Shivarudrappa, Narendra Kumar, Mysore Nagaraj, Anil Kumar, Pai, Nagesh Brahmavar, Rajagopal, Rajendra, Siddika, Nayeema   +5 more
core   +2 more sources

Sildenafil or Vardenafil Nonresponders’ Erectile Response to Tadalafil

Urology Journal, 2009
Introduction: Erectile dysfunction has usually been treated by a phosphodiesterase 5 inhibitor in men, especially in the past decade. Although sildenafil and vardenafil are widely used, there is a high percentage of people who do not respond to these ...
Berat Cem Ozgur, Faruk Gonenc, Ahmet H Yazicioglu   +2 more
doaj  

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension

Drug Delivery, 2018
Pulmonary arterial hypertension (PAH) can be relieved by pharmacological interventions, especially the targeted drug, which is classified into endothelin receptor antagonist, phosphodiesterase 5 inhibitor, prostaglandin I2, soluble guanylate cyclase ...
Sumei Wang, Miao Yu, Xiangchun Zheng, Shangjuan Dong   +3 more
doaj   +1 more source

Monitorização da adulteração de suplementos alimentares à base de plantas comercializados em Portugal com inibidores de fosfodiesterase tipo 5 (PDE-5) [PDF]

, 2015
Na ultima década, assistiu-se a um consumo crescente de suplementos alimentares pela população mundial, especialmente, no que diz respeito ao consumo de suplementos alimentares a base de plantas 1.
Amaral, Joana S., Oliveira, Beatriz, Rocha, T., Santos, J.   +3 more
core  

Physicochemical characteristics and ex vivo skin permeability for three phosphodiesterase 5 inhibitors (sildenafil, tadalafil and vardenafil): A proof-of-concept study for topical penile therapy

Journal of Drug Delivery Science and Technology, 2022
S. A. Mohamed, Wesam W. Mustafa, Hesham Salem, Mahmoud Elrehany, R. Rofaeil, Hamdy Abdelkader   +5 more
semanticscholar   +1 more source

Pharmacological effect of one icv dose of Allopregnanolone in female rat: behavioural profile [PDF]

, 2015
We have previously observed that intracerebroventricular allopregnanolone (ALLO) injection produced an anxiolytic effect and inhibited sexual receptivity when the test was performed in a separate manner. Also, ALLO reverts learning deficit in female rats
Cabrera Kreiker, Ricardo Jorge, Escudero, Carla Gimena, García Menéndez, Sebastián Marcelo Manuel, Giuliani, Fernando Alfredo, Laconi, Myriam Raquel, Pelegrina, Laura Tatiana   +5 more
core  

PVC membrane, coated-wire, and carbon-paste electrodes for potentiometric determination of vardenafil hydrochloride in tablet formulations and urine samples

Sensors International, 2022
Hazem M. Abu Shawish, S. Saadeh, Suha T. Al-kahlout   +2 more
semanticscholar   +1 more source

Evidenzbasierte Therapie des Raynaud-Syndroms [PDF]

, 2018
Zusammenfassung: Das Raynaud-Syndrom ist mit einer Prävalenz von 3-5% ein häufiges klinisches Problem. Dennoch ist die Wirkung der meisten Therapiemöglichkeiten nur unzureichend durch kontrollierte Studien belegt. Zu den Therapien mit höherem Evidenzgrad
Ciurea, A., Distler, J., Distler, M., Distler, O., Kyburz, D., Müller-Ladner, U., Reich, K.   +6 more
core